Amgen Turkey opened its head office in Istanbul in 2010 and acquired Gensenta Pharmaceuticals (GpH) for 700 million dollars in 2012 which is one of Turkey's leading pharmaceutical companies and one of the first biosimilar manufacturers. Thus, Amgen has gained the title of the largest foreign investor in the field of health and has become an important force in Turkey, Africa and the Middle East region. This was one of Turkey's leading pharmaceutical companies and one of the first biosimilar manufacturers. By combining its international capital strength and know-how of Gensenta's experience and leadership in the production of parenteral products, Amgen contributes to the domestic production, R&D, and export priorities set in the Turkish Pharmaceutical Strategy Report, especially in the fields of oncology and biotechnology.